<DOC>
	<DOCNO>NCT01966978</DOCNO>
	<brief_summary>The aim clinical trial ass compare effect insulin detemir combination liraglutide metformin versus insulin detemir combination insulin aspart metformin subject uncontrolled Type 2 Diabetes ( A1c &gt; 10 % ) .</brief_summary>
	<brief_title>The Effect Simple Basal Insulin Titration , Metformin Plus Liraglutide Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study</brief_title>
	<detailed_description>The aim study compare GLP-1 plus basal insulin metformin treatment regimen basal-bolus plus metformin treatment regimen patient uncontrolled ( HbA1c &gt; 10 % ) type 2 diabetes . The investigator compare two regimen respect efficacy improve glycemic control , rate hypoglycemia , change weight , effect patient quality life , treatment burden , physician time , well healthcare related cost . The investigator hypothesize 26 week randomization two treatment regimen similar percentage patient reach A1c level &lt; 7.0 % , patient GLP-1 plus basal insulin strategy achieve composite end point A1c level &lt; 7.0 % without severe hypoglycemia significant weight gain .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1 . Clinical diagnosis type 2 diabetes confirm HbA1c level &gt; 10 % time enrollment , regardless prior current treatment regimen , time since diagnosis . 1 . Age &lt; 18 feasibility safety treatment regimen first establish adult population ; successful , subsequent pediatric study propose ; 2 . Type 1 diabetes purposefully withhold mealtime insulin contraindicate ; 3 . Clinical state require inpatient admission/treatment ; 4 . Contraindication strong caution study medication : 1 . Creatinine 1.4 mg/dl woman 1.5 mg/dl men ( per metformin label ) 2 . History lactic acidosis ( per metformin label ) 3 . Advanced hepatic cardiac disease ( per metformin label ) 4 . Age &gt; 80 year ( per metformin label ) 5 . Chronic alcohol use ( &gt; 14 drinks/week ) 6 . History pancreatitis ( per liraglutide label ) 7 . Personal family history medullary thyroid cancer MEN syndrome ( per liraglutide label ) 8 . Pregnancy lactation ( per liraglutide label ) 5 . Any serious unstable medical condition would interfere treatment assignment well outcome measurement ; 6 . Any scheduled elective procedures/surgeries ; 7 . Active infection , include osteomyelitis ; 8 . Not willing participate , unable keep project appointment , unwillingness receive injectable treatment ; unwillingness perform 7point glucose profile 2 consecutive day week prior Randomization ( visit 1 ) week prior visit 6 9 . Non English speaking .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Insulin</keyword>
	<keyword>Insulin , Long-Acting</keyword>
	<keyword>Insulin , Short Acting</keyword>
	<keyword>Detemir</keyword>
	<keyword>Liraglutide</keyword>
	<keyword>GLP-1</keyword>
	<keyword>Glucagon Like Peptide</keyword>
	<keyword>Metformin</keyword>
	<keyword>Uncontrolled Diabetes</keyword>
	<keyword>Elevated A1c</keyword>
	<keyword>Incretins</keyword>
</DOC>